Chipscreen(SH:688321) Xin Lang Cai Jing·2025-10-31 04:40Core Viewpoint - Shenzhen MicuRx Pharmaceuticals, Inc. reported a significant revenue growth of 40.12% year-on-year for the first three quarters of 2025, driven by increased sales of its products, particularly Sidaracizumab and Siglec-1 [1] Financial Performance - The company achieved a total revenue of 674 million yuan in the first three quarters [1] - Sales revenue for Sidaracizumab increased by 18.76% year-on-year [1] - Sales revenue for Siglec-1 surged by 136.13% year-on-year [1] Product Development and Strategy - MicuRx Pharmaceuticals has developed a global strategy based on early research in China, leveraging a team of top scientists with extensive experience in relevant fields [1] - The company employs an integrated technology platform that combines AI-assisted design and chemical genomics, facilitating the entire process from basic research to clinical translation [1] - As of June 30, the company has two innovative drugs with multiple indications globally marketed, focusing on five major areas: malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases, and antiviral treatments [1]